Renal

Localized

T1b or greater (has not spread beyond the kidney)

IRB#16576
Atezolizumab vs placebo as adjuvant therapy following nephrectomy

No Prior Systemic Therapy

IRB#16300
Merck 3475

IRB#9241
Pazopanib vs. Placebo in Patients with mRCC

Metastasisectomy Candidate

Cytoreductive Nephrectomy Candidate

Clear Cell

No trials Currently Available

IRB# 11283
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

IRB# 16085
S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

No Prior Systemic Therapy

Non- Clear Cell

No Trials Currently Available

IRB# 9241
Pazopanib vs. Placebo in Patients with mRCC

IRB# 11283
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

IRB# 16085
S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Metastatic/advanced

No Trials Currently Available